NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

What's the purpose of this trial?

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.

This trial is currently open and accepting patients.


What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

* ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Patients must be \>= 12 months and =\< 21 years of age at the time of study enrollment
* ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Patients with recurrent or refractory solid tumors, including non-Hodgkin lymphomas, histiocytoses (e.g. langerhans cell histiocytosis \[LCH\], juvenile xanthogranuloma \[JXG\], histiocytic sarcoma), and central nervous system (CNS) tumors are eligible; patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG); in cases where patient enrolls prior to histologic confirmation of recurrent disease, patient is ineligible and should be withdrawn from study if histology fails to confirm recurrence; please note: Patients with Hodgkin lymphoma and plexiform neurofibroma are not eligible
* ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Tumor Testing Requirement: Tumor sample availability requirement for stage 1 of Pediatric MATCH (patients enrolled from start of study in July 2017 through 12/31/21); Patients must have an formalin-fixed paraffin-embedded (FFPE) tumor sample available for MATCH study testing from a biopsy or surgery that was performed at any point after initial tumor recurrence/progression, or be planned to have a procedure to obtain such a sample that is considered to be of potential benefit by the treating clinicians; a tumor sample from a clinically performed diagnostic (pre-treatment) biopsy will be acceptable for enrollment onto Pediatric MATCH only for children with high-grade gliomas of the brainstem (diffuse intrinsic pontine gliomas) or thalamus

* Please note: Samples that have been decalcified using standardly utilized acid-based decalcification methods are not generally suitable for MATCH study testing; the nucleic acids will have been degraded in the decalcification process
* ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Tumor molecular profiling report availability requirement for Stage 2 of Pediatric MATCH (patients enrolled starting 2022): In stage 2 of the study, no tumor samples will be submitted for centralized clinical tumor profiling; instead, a tumor molecular profiling report from a College of American Pathologists (CAP)/ Clinical Laboratory Improvements Amendments (CLIA)-approved testing laboratory must be submitted for review by the Molecular Review Committee (MRC)

* This molecular profiling must have been performed on a tumor sample that was obtained at any point after initial tumor recurrence/progression and must be accompanied by a pathology report for the same tumor specimen; a molecular profiling report for a diagnostic (pre-treatment) tumor sample will be acceptable for enrollment onto Pediatric MATCH only for children with high-grade gliomas of the brainstem (diffuse intrinsic pontine gliomas) or thalamus. In the event that molecular profiling reports are available from multiple timepoints, the most recent report should be prioritized for study submission
* ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Karnofsky \>= 50% for patients \> 16 years of age and Lansky \>= 50 for patients =\< 16 years of age); note: neurologic deficits in patients with central nervous system (CNS) tumors must have been stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
* ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Patients must have radiographically measurable disease; measurable disease based on imaging obtained less than or equal to 56 days prior to enrollment; patients with neuroblastoma who do not have measurable disease but have metaiodobenzylguanidine (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as any lesion that is at minimum 10 mm in one dimension on standard magnetic resonance imaging (MRI) or computed tomography (CT)

* Note: The following do not qualify as measurable disease:

* Malignant fluid collections (e.g., ascites, pleural effusions)
* Bone marrow infiltration except that detected by MIBG scan for neuroblastoma
* Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography \[PET\] scans) except as noted for neuroblastoma
* Elevated tumor markers in plasma or CSF
* Previously radiated lesions that have not demonstrated clear progression post radiation
* Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
* GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: NOTE: patient does not need to meet all subprotocol criteria at time of enrollment onto the APEC1621SC screening protocol, but will need to meet all criteria prior to enrollment on any assigned treatment subprotocol. Patients must be enrolled onto a subprotocol within 2 weeks (14 days) of treatment assignment
* GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Karnofsky \>= 50% for patients \> 16 years of age and Lansky \>= 50 for patients =\< 16 years of age); Note: neurologic deficits in patients with CNS tumors must have been stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
* GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: At the time of treatment with subprotocol specified therapy, the patients must have radiographically measurable disease; patients with neuroblastoma who do not have measurable disease but have MIBG+ evaluable are eligible; measurable disease in patients with CNS involvement is defined as any lesion that is at minimum 10 mm in one dimension on standard MRI or CT

* Note: The following do not qualify as measurable disease:

* Malignant fluid collections (e.g., ascites, pleural effusions)
* Bone marrow infiltration except that detected by MIBG scan for neuroblastoma
* Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography \[PET\] scans) except as noted for neuroblastoma
* Elevated tumor markers in plasma or CSF
* Previously radiated lesions that have not demonstrated clear progression post radiation
* Leptomeningeal lesions that do not meet the measurement requirements for RECIST 1.1
* GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: At the time of enrollment onto a subprotocol, the following general criteria for initiation of therapy will be required:

* Patients must have fully recovered from the acute toxic effects of all prior anticancer therapy and must meet the following minimum duration from prior anticancer directed therapy prior to enrollment to the subprotocol; if after the required timeframe, the numerical eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately

* Cytotoxic chemotherapy or other anticancer agents known to be myelosuppressive: for agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment \>= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)
* Anticancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil counts \[ANC\]): \>= 7 days after the last dose of agent; for agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment
* Antibodies: \>= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =\< 1
* Corticosteroids: If used to modify immune adverse events related to prior therapy, \>= 14 days must have elapsed since last dose of corticosteroid
* Hematopoietic growth factors: \>= 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator
* Interleukins, interferons and cytokines (other than hematopoietic growth factors): \>= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)
* Stem cell infusions (with or without total-body irradiation \[TBI\]):

* Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: \>= 84 days after infusion and no evidence of graft versus host disease (GVHD)
* Autologous stem cell infusion including boost infusion: \>= 42 days
* Cellular therapy: \>= 42 days after the completion of any type of cellular therapy (e.g. modified T cells, natural killer (NK) cells, dendritic cells, etc.)
* X-ray therapy (XRT)/External Beam Irradiation including Protons: \>= 14 days after local XRT; \>= 150 days after TBI, craniospinal XRT or if radiation to \>= 50% of the pelvis; \>= 42 days if other substantial bone marrow (BM) radiation; note: radiation may not be delivered to "measurable disease" tumor site(s) being used to follow response to subprotocol treatment
* Radiopharmaceutical therapy (e.g., radiolabeled antibody, 131I-MIBG): \>= 42 days after systemically administered radiopharmaceutical therapy
* GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: For patients with solid tumors without known bone marrow involvement:

* Peripheral absolute neutrophil count (ANC) \>= 1000/mm\^3
* Platelet count \>= 100,000/mm\^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
* GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity
* GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 ml/min/1.73 m\^2 or a serum creatinine based on age/gender as follows:

* Age: 1 to \< 2 years; maximum serum creatinine (mg/dL): male 0.6; female 0.6
* Age: 2 to \< 6 years; maximum serum creatinine (mg/dL): male 0.8; female 0.8
* Age: 6 to \< 10 years; maximum serum creatinine (mg/dL): male 1; female 1
* Age: 10 to \< 13 years; maximum serum creatinine (mg/dL): male 1.2; female 1.2
* Age: 13 to \< 16 years; maximum serum creatinine (mg/dL): male 1.5; female 1.4
* Age: \>= 16 years; maximum serum creatinine (mg/dL): male 1.7; female 1.4
* GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Bilirubin (sum of conjugated + unconjugated) =\< 1.5 x upper limit of normal (ULN) for age
* GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Serum glutamate pyruvate transaminase (SGPT) (alanine transferase \[ALT\]) =\< 135 U/L (for the purpose of this study, the ULN for SGPT is 45 U/L)
* GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Patients must be able to swallow intact capsules/tablets, unless otherwise specified in the subprotocol to which they are assigned
* GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Agent specific limitations on prior therapy will be included with specific treatment subprotocols

Exclusion Criteria:

* GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies, or because there is currently no available information regarding human fetal or teratogenic toxicities; pregnancy tests must be obtained in females who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
* GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Concomitant medications

* Corticosteroids: at the time of consent and enrollment to regimen specific subprotocols, patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment to the subprotocol will not be eligible; if used to modify immune adverse events related to prior therapy, \>= 14 days must have elapsed since last dose of corticosteroid
* Investigational drugs: patients must meet criteria for prior therapy at the time of consent and enrollment to a subprotocol; other investigational agents may not be administered to patients while they are receiving study drug as part of a subprotocol
* Anticancer agents: patients must meet criteria for prior therapy at the time of consent and enrollment to a subprotocol; other investigational agents may not be administered to patients while they are receiving study drug as part of a subprotocol
* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible
* GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Patients who have an uncontrolled infection are not eligible
* GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Patients who have had a prior solid organ transplant are not eligible
* GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Additional agent specific criteria will be included with specific treatment subprotocols

Additional Trial Information

Phase 2

Enrollment: 2,316 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Alabama

University of Alabama at Birmingham O'Neal Comprehensive Cancer Center at UAB

Birmingham, AL

Open and Accepting

Children's of Alabama

Birmingham, AL

Open and Accepting

Alaska

Providence Alaska Medical Center

Anchorage, AK

Open and Accepting

Arizona

Banner Children's at Desert

Mesa, AZ

Open and Accepting

Phoenix Children's Hospital

Phoenix, AZ

Open and Accepting

Banner - University Medical Center Tucson Banner Health

Tucson, AZ

Open and Accepting

Arkansas

Arkansas Children's Hospital

Little Rock, AR

Open and Accepting

California

Loma Linda University Cancer Center

Loma Linda, CA

Open and Accepting

Miller Children's and Women's Hospital Long Beach

Long Beach, CA

Open and Accepting

Children's Hospital Los Angeles

Los Angeles, CA

Open and Accepting

Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute

Los Angeles, CA

Open and Accepting

UCLA - Mattel Children's Hospital

Los Angeles, CA

Open and Accepting

Valley Children's Hospital

Madera, CA

Open and Accepting

UCSF Benioff Children's Hospital Oakland

Oakland, CA

Open and Accepting

Kaiser Permanente (Oakland Medical Center)

Oakland, CA

Open and Accepting

Children's Hospital Orange County

Orange, CA

Open and Accepting

Stanford Univ Med Ctr. / Lucile Packard Children's Hosp

Palo Alto, CA

Open and Accepting

University of California Davis Comprehensive Cancer Center

Sacramento, CA

Open and Accepting

Rady Children's Hospital

San Diego, CA

Open and Accepting

Naval Medical Center (San Diego)

San Diego, CA

Open and Accepting

Colorado

The Children's Hospital of Colorado

Aurora, CO

Open and Accepting

Rocky Mountain Cancer Centers - Denver Midtown Denver - Midtown

Denver, CO

Open and Accepting

Connecticut

Connecticut Children's Medical Center

Hartford, CT

Open and Accepting

Yale Cancer Center Smilow Cancer Hospital at Yale-New Haven

New Haven, CT

Open and Accepting

Delaware

Alfred I. DuPont Hospital for Children

Wilmington, DE

Open and Accepting

Florida

Broward Oncology Associates, PA

Fort Lauderdale, FL

Open and Accepting

Golisano Children's Hospital of Southwest Florida

Fort Myers, FL

Open and Accepting

University of Florida Health Science Center - Gainesville

Gainesville, FL

Open and Accepting

Memorial Regional Hospital/Joe DiMaggio Children's Hospital

Hollywood, FL

Open and Accepting

Nemour's Children's Health (Jacksonville)

Jacksonville, FL

Open and Accepting

Nicklaus Children's Hospital

Miami, FL

Open and Accepting

AdventHealth (East Orlando)

Orlando, FL

Open and Accepting

Arnold Palmer Hospital for Children

Orlando, FL

Open and Accepting

Nemours Children's Hospital

Orlando, FL

Open and Accepting

Sacred Heart Medical Oncology Group

Pensacola, FL

Open and Accepting

Johns Hopkins All Children's Hospital

Saint Petersburg, FL

Open and Accepting

Tampa General Hospital Cancer Institute

Tampa, FL

Open and Accepting

Saint Mary's Hospital

West Palm Beach, FL

Open and Accepting

Georgia

Children's Healthcare of Atlanta

Atlanta, GA

Open and Accepting

Memorial Health University Medical Center

Savannah, GA

Open and Accepting

Hawaii

Kapiolani Medical Center for Women and Children

Honolulu, HI

Open and Accepting

Illinois

Robert H. Lurie Comprehensive Cancer Center Northwestern University

Chicago, IL

Open and Accepting

University of Illinois

Chicago, IL

Open and Accepting

University of Chicago Medicine Comprehensive Cancer Center

Chicago, IL

Open and Accepting

Loyola University Medical Center Cardinal Bernardin Cancer Center

Maywood, IL

Open and Accepting

Saint Jude Midwest Affiliate

Peoria, IL

Open and Accepting

Southern Illinois University School of Medicine - Simmons Cancer Institute

Springfield, IL

Open and Accepting

Indiana

IU Simon Cancer Center Indiana University

Indianapolis, IN

Open and Accepting

Ascension Saint Vincent Indianapolis Hospital

Indianapolis, IN

Open and Accepting

Iowa

Holden Comprehensive Cancer Center University of Iowa Hospitals and Clinics

Iowa City, IA

Open and Accepting

Blank Children's Hospital

Des Moines, IA

Open and Accepting

Kentucky

UK Markey Cancer Center University of Kentucky

Lexington, KY

Open and Accepting

Norton Cancer Institute (St. Matthews) St. Matthews Campus

Louisville, KY

Open and Accepting

Louisiana

Ochsner Medical Center

Jefferson, LA

Open and Accepting

Children's Hospital New Orleans

New Orleans, LA

Open and Accepting

Maine

Eastern Maine Medical Center

Bangor, ME

Open and Accepting

Maryland

Sinai Hospital LifeBridge Health

Baltimore, MD

Open and Accepting

Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Medicine

Baltimore, MD

Open and Accepting

National Institutes of Health (Bethesda)

Bethesda, MD

Temporarily Suspended

Massachusetts

Massachusetts General Hospital

Boston, MA

Open and Accepting

Dana-Farber Cancer Institute (Main)

Boston, MA

Open and Accepting

UMass Memorial Medical Center - University Campus

Worcester, MA

Open and Accepting

Michigan

University of Michigan Comprehensive Cancer Center Rogel Cancer Center

Ann Arbor, MI

Open and Accepting

Barbara Ann Karmanos Cancer Institute Wayne State University

Detroit, MI

Open and Accepting

Michigan State University Clinical Center

East Lansing, MI

Open and Accepting

Spectrum Health

Grand Rapids, MI

Open and Accepting

Bronson Methodist Hospital

Kalamazoo, MI

Open and Accepting

Minnesota

Children's Hospitals and Clinics of Minnesota

Minneapolis, MN

Open and Accepting

University of Minnesota - Masonic Cancer Center University of Minnesota

Minneapolis, MN

Open and Accepting

Mayo Clinic (Rochester)

Rochester, MN

Open and Accepting

Mississippi

University of Mississippi Medical Center

Jackson, MS

Open and Accepting

Missouri

Children's Mercy Hospitals and Clinics

Kansas City, MO

Open and Accepting

Cardinal Glennon Children's Medical Center

Saint Louis, MO

Open and Accepting

Washington University School of Medicine

Saint Louis, MO

Open and Accepting

Mercy Hospital St. Louis David C. Pratt Cancer Center

St. Louis, MO

Open and Accepting

Nebraska

Children's Hospital and Medical Center of Omaha

Omaha, NE

Open and Accepting

Nevada

University Medical Center of Southern Nevada

Las Vegas, NV

Temporarily Suspended

Sunrise Hospital and Medical Center

Las Vegas, NV

Open and Accepting

Alliance for Childhood Diseases/Cure 4 the Kids Foundation

Las Vegas, NV

Open and Accepting

Summerlin Hospital Medical Center

Las Vegas, NV

Open and Accepting

New Hampshire

Dartmouth-Hitchcock Medical Center Norris Cotton Cancer Center

Lebanon, NH

Open and Accepting

New Jersey

John Theurer Cancer Center Hackensack Meridian Health

Hackensack, NJ

Open and Accepting

Morristown Medical Center Atlantic Health System

Morristown, NJ

Open and Accepting

Saint Peter's University Hospital

New Brunswick, NJ

Open and Accepting

Rutgers Cancer Institute of New Jersey Rutgers, The State University of New Jersey

New Brunswick, NJ

Open and Accepting

New York

Memorial Sloan Kettering Cancer Center

New York, NY

Open and Accepting

Albany Medical Cancer Center

Albany, NY

Open and Accepting

Roswell Park Cancer Institute

Buffalo, NY

Open and Accepting

Montefiore Medical Center (Moses Campus)

New York, NY

Open and Accepting

NewYork-Presbyterian/ Weill Cornell Medical Center

New York, NY

Open and Accepting

Steven and Alexandra Cohen Children's Medical Center

North New Hyde Park, NY

Open and Accepting

University of Rochester Medical Center James P. Wilmot Cancer Center

Rochester, NY

Open and Accepting

Stony Brook University Hospital

Stony Brook, NY

Open and Accepting

SUNY Upstate Medical University State University of New York

Syracuse, NY

Open and Accepting

New York Medical College

Valhalla, NY

Open and Accepting

North Carolina

UNC Lineberger Comprehensive Cancer Center University of North Carolina

Chapel Hill, NC

Open and Accepting

Wake Forest Baptist Atrium Health

Winston-Salem, NC

Open and Accepting

Mission Hospital Inc Memorial Campus

Asheville, NC

Open and Accepting

Carolinas Medical Center

Charlotte, NC

Open and Accepting

Novant Health Presbyterian Medical Center Novant Health

Charlotte, NC

Open and Accepting

Duke Cancer Center Duke University Medical Center

Durham, NC

Open and Accepting

East Carolina University Vidant Cancer Care Eddie and Jo Allison Smith Tower

Greenville, NC

Open and Accepting

Ohio

Akron Children's Hospital

Akron, OH

Open and Accepting

Cincinnati Children's Hospital Medical Center

Cincinnati, OH

Open and Accepting

Rainbow Babies and Childrens Hospital

Cleveland, OH

Open and Accepting

Cleveland Clinic Taussig Cancer Institute

Cleveland, OH

Open and Accepting

Nationwide Children's Hospital

Columbus, OH

Open and Accepting

Dayton Children's Hospital

Dayton, OH

Open and Accepting

ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital

Toledo, OH

Open and Accepting

Oklahoma

University of Oklahoma Health Sciences Center

Oklahoma City, OK

Open and Accepting

Oregon

Legacy Emanuel Children's Hospital

Portland, OR

Open and Accepting

Oregon Health and Science University OHSU Knight Cancer Institute

Portland, OR

Open and Accepting

Pennsylvania

Lehigh Valley Hospital-Cedar Crest

Allentown, PA

Open and Accepting

Geisinger Medical Center - Danville

Danville, PA

Open and Accepting

Children's Hospital of Philadelphia

Philadelphia, PA

Open and Accepting

UPMC Children's Hospital of Pittsburgh

Pittsburgh, PA

Open and Accepting

Rhode Island

Rhode Island Hospital

Providence, RI

Open and Accepting

South Carolina

Prisma Health Richland Hospital

Columbia, SC

Open and Accepting

BI-LO Charities Children's Cancer Center

Greenville, SC

Open and Accepting

South Dakota

Sanford USD Medical Center (Sioux Falls)

Sioux Falls, SD

Open and Accepting

Tennessee

East Tennessee Childrens Hospital

Knoxville, TN

Open and Accepting

St. Jude Children's Research Center

Memphis, TN

Open and Accepting

TriStar Centennial Medical Center

Nashville, TN

Open and Accepting

Vanderbilt-Ingram Cancer Center Henry-Joyce Cancer Clinic

Nashville, TN

Open and Accepting

Texas

Dell Children's Medical Center of Central Texas

Austin, TX

Open and Accepting

Driscoll Children's Hospital

Corpus Christi, TX

Open and Accepting

Medical City Dallas Hospital

Dallas, TX

Open and Accepting

Simmons Comprehensive Cancer Center

Dallas, TX

Open and Accepting

El Paso Children's Hospital

El Paso, TX

Open and Accepting

Cook Children's Medical Center

Fort Worth, TX

Open and Accepting

Baylor College of Medicine - Dan L. Duncan Comprehensive Cancer Center

Houston, TX

Open and Accepting

MD Anderson Cancer Center The University of Texas

Houston, TX

Open and Accepting

Covenant Medical Center (Lubbock)

Lubbock, TX

Open and Accepting

UMC Cancer Center / UMC Health System

Lubbock, TX

Open and Accepting

Children's Hospital of San Antonio

San Antonio, TX

Open and Accepting

Methodist Children's Hospital of South Texas

San Antonio, TX

Open and Accepting

Baylor Scott & White Hospital

Temple, TX

Open and Accepting

Utah

Primary Children's Hospital

Salt Lake City, UT

Open and Accepting

Vermont

University of Vermont and State Agricultural College

Burlington, VT

Open and Accepting

Virginia

Children's Hospital of The King's Daughters

Norfolk, VA

Open and Accepting

Naval Medical Center - Portsmouth

Portsmouth, VA

Open and Accepting

Massey Cancer Center Virginia Commonwealth University (VCU Health)

Richmond, VA

Open and Accepting

Washington

Seattle Children's Hospital

Seattle, WA

Open and Accepting

Providence Sacred Heart Medical Center and Children's Hospital

Spokane, WA

Open and Accepting

Mary Bridge Children's Hospital and Health Center

Tacoma, WA

Open and Accepting

Madigan Army Medical Center

Tacoma, WA

Open and Accepting

Washington, D.C.

MedStar Georgetown University Hospital

Washington, DC

Open and Accepting

Children's National Medical Center

Washington, DC

Open and Accepting

Wisconsin

UW Carbone Cancer Center University of Wisconsin Health

Madison, WI

Open and Accepting

Marshfield Medical Center - Hospital

Marshfield, WI

Open and Accepting

Children's Hospital of Wisconsin

Milwaukee, WI

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message